Results 11 to 20 of about 5,560 (153)
Clinical guidelines highlight for the hospitalist: Management of cyclic vomiting syndrome in children [PDF]
J Hosp MedJournal of Hospital Medicine, Volume 21, Issue 3, Page 291-293, March 2026.
Yamileth N. Hernandez, Hannah M. Gardner
wiley +2 more sources
Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study [PDF]
Health Science Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background and Aims Primary dysmenorrhea is a prevalent condition that causes significant menstrual pain and discomfort, impacting many women′s daily activities. The Substance P/NK1 receptor (SP/NK1R) pathway has been linked to the pain mechanisms underlying dysmenorrhea, yet its potential as a therapeutic target remains inadequately explored.
Riffat Mehboob +8 more
wiley +2 more sources
Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma [PDF]
Cancers (Basel)Simple Summary Diffuse intrinsic pontine glioma (DIPG) is a devastating childhood brain tumor. The median survival of DIPG is 16 to 24 months, regardless of the treatment received.
Miguel Muñoz, M. Rosso
semanticscholar +2 more sources
Utility of Aprepitant in the Management of Pediatric Patients with Cyclical Vomiting Syndrome [PDF]
Medicines (Basel)Introduction: Cyclical vomiting syndrome (CVS) is a recurrent debilitating illness characterized by intense episodes of nausea and emesis with widely varied pharmacological management across the country.
A. Thavamani +4 more
semanticscholar +2 more sources
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis
Medicine, 2023 Background: Postoperative nausea and vomiting (PONV) is one of the common adverse reactions after surgery. Recent randomized controlled trials (RCTs) investigating antiemetic drugs suggest that aprepitant has the strongest antiemetic effect of any single
Yingchao Liu +10 more
semanticscholar +1 more source
Cancer Medicine, 2023 Non‐inferiority of NEPA (fixed combination of NK1 receptor antagonist (RA), netupitant, and 5‐HT3RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide (AC) and non‐AC
L. Zelek +3 more
semanticscholar +1 more source
pharma-kritik, 2004 In Kombination mit anderen hochwirksamen Antiemetika kann Aprepitant bei einer stark emetogenen Chemotherapie, besonders bei der Verabreichung von Cisplatin, Brechreiz und Erbrechen verhüten helfen.
openaire +1 more source
International Journal of Molecular Sciences, 2023 The substance P (SP)/neurokinin-1 receptor (NK-1R) system is involved in cancer progression. NK-1R, activated by SP, promotes tumor cell proliferation and migration, angiogenesis, the Warburg effect, and the prevention of apoptosis.
R. Coveñas +3 more
semanticscholar +1 more source
Biofactors, 2023 Glioblastoma multiforme (GBM) is the most malignant type of cerebral neoplasm in adults with a poor prognosis. Currently, combination therapy with different anti‐cancer agents is at the forefront of GBM research.
Safieh Ebrahimi +5 more
semanticscholar +1 more source
Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation
BMC Cancer, 2023 Background Aprepitant, as a neurokinin-1 receptor (NK-1R) antagonist, originally applied for curing chemotherapy-induced nausea and vomiting, has been reported to have significant antitumor effect on several malignant tumors.
Xueyan Cao +9 more
semanticscholar +1 more source